PAUF-detecting Diagnostic Kit
A Powerful Tool for Screening and Detection of Pancreatic Cancer
Prestige Biopharma is developing a first-in-class diagnostic kit for the detection of Pancreatic Adenocarcinoma Upregulated Factor (PAUF). PAUF is a distinctive tumor-specific biomarker overexpressed in over 80% of pancreatice cnacer cases, associated with early progression and metastasis.
Through the successful development of the diagnostic kit on the top of our novel anti-PAUF antibody PBP1510 for the treatment, we believe our efforts will significantly benefit patients with pancreatic cancer and contribute to improving human health, which is exactly what our mission ‘Innovation for Life‘ stands for.
The need for a new pancreatic cancer treatment.
Pancreatic cancer is the seventh leading cause of cancer deaths worldwide (Rawla, Sunkara and Gaduputi, 2019). Pancreatic cancer occurs when cells in the pancreas develop mutations in their DNA and grow uncontrollably. Untreated pancreatic cancer spreads to nearby organs and blood vessels. Despite the availability of several treatments on the market, long-term overall survival remains poor and the need for better pancreatic cancer treatment is still unfulfilled. Thus, early detection and diagnosis are crucial for improving patient outcomes and increasing survival rates.
5-Year Survival Rate of Pancreatic Cancer Patients
5-Year Survival Rate of Liver Cancer Patients